IS6803A - GABA eflar í meðhöndlun á sjúkdómum sem varða minnkaða taugasteróíð virkni - Google Patents

GABA eflar í meðhöndlun á sjúkdómum sem varða minnkaða taugasteróíð virkni

Info

Publication number: IS6803A
Authority: IS; Iceland
Prior art keywords: management; diseases related; steroid activity; decreased neuronal; gaba
Prior art date: 2000-11-20

Application number

IS6803A

Other languages

English (en)

Other versions

IS2427B (is

Inventor

Ebert Bjarke

Høngaard Andersen Peter

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-20

Filing date

2003-04-30

Publication date

2003-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-30 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2003-04-30 Publication of IS6803A publication Critical patent/IS6803A/is

2008-10-15 Publication of IS2427B publication Critical patent/IS2427B/is

Links

230000003247 decreasing effect Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000000694 effects Effects 0.000 title 1
229960003692 gamma aminobutyric acid Drugs 0.000 title 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title 1
230000001537 neural effect Effects 0.000 title 1
150000003431 steroids Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)

IS6803A 2000-11-20 2003-04-30 Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan IS2427B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200001743		2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en)	2000-11-20	2001-11-20	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (2)

Publication Number	Publication Date
IS6803A true IS6803A (is)	2003-04-30
IS2427B IS2427B (is)	2008-10-15

Family

ID=8159857

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6803A IS2427B (is)	2000-11-20	2003-04-30	Notkun á gaboxadóli til meðhöndlunar á fyrirtíðatruflun, eftirburðarþunglyndi eða eftirtíðatengdri vanlíðan

Country Status (33)

Country	Link
US (2)	US20040024038A1 (is)
EP (1)	EP1337247B1 (is)
JP (1)	JP4152186B2 (is)
KR (1)	KR100865651B1 (is)
CN (1)	CN1318027C (is)
AR (1)	AR031473A1 (is)
AT (1)	ATE336242T1 (is)
AU (2)	AU2351402A (is)
BG (1)	BG107909A (is)
BR (1)	BR0115668A (is)
CA (1)	CA2429220C (is)
CY (1)	CY1106209T1 (is)
CZ (1)	CZ20031383A3 (is)
DE (1)	DE60122368T2 (is)
DK (1)	DK1337247T3 (is)
EA (1)	EA007287B1 (is)
ES (1)	ES2266308T3 (is)
HR (1)	HRP20030404A2 (is)
HU (1)	HUP0400505A3 (is)
IL (1)	IL155587A0 (is)
IS (1)	IS2427B (is)
ME (1)	MEP6408A (is)
MX (1)	MXPA03004349A (is)
NO (1)	NO20032271D0 (is)
NZ (1)	NZ525520A (is)
PL (1)	PL361051A1 (is)
PT (1)	PT1337247E (is)
SI (1)	SI1337247T1 (is)
SK (1)	SK7682003A3 (is)
UA (1)	UA77403C2 (is)
WO (1)	WO2002040009A1 (is)
YU (1)	YU39003A (is)
ZA (1)	ZA200303289B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
WO2003045411A2 (de) *	2001-11-26	2003-06-05	Finzelberg Gmbh & Co. Kg	Ingwer-extraktzubereitung
EP1641456B1 (en) *	2003-06-25	2010-03-03	H. Lundbeck A/S	Gaboxadol for treating depression and other affective disorders
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
MXPA06015196A (es) *	2004-06-29	2007-03-15	Lundbeck & Co As H	Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
WO2006012563A2 (en) *	2004-07-23	2006-02-02	The Regents Of The University Of California	Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
EP1848420A4 (en)	2005-01-28	2008-01-23	Merck & Co Inc	POLYMORPH SHAPES OF A GABAA AGONIST
US20070122507A1 (en) *	2005-05-26	2007-05-31	Palu Afa K	Histone deacetylase and tumor necrosis factor converting enzyme inhibition
WO2008085205A2 (en) *	2006-12-29	2008-07-17	Prodea Systems, Inc.	System and method for providing network support services and premises gateway support infrastructure
WO2008141112A1 (en) *	2007-05-09	2008-11-20	Cenerx Biopharma, Inc.	Methods of treating rett syndrome
CN101585862B (zh) *	2008-05-20	2014-12-17	梅克芳股份公司	甾族化合物
WO2012173634A1 (en) *	2011-06-16	2012-12-20	Solace Lifesciences, Inc.	Systems and methods for balancing and maintaining the health of the human autonomic nervous system
RU2496496C1 (ru) *	2012-10-04	2013-10-27	Исаак Григорьевич Гитлин	Фармацевтическая композиция, обладающая гамк-ергической активностью
CN108024997A (zh)	2015-07-17	2018-05-11	奥维德医疗公司	用加波沙朵治疗发育障碍的方法
KR20230050474A (ko) *	2016-08-11	2023-04-14	오비드 테라퓨틱스 인크.	간질 장애의 치료를 위한 방법 및 조성물
US20180338959A1 (en) *	2017-05-24	2018-11-29	Ovid Therapeutics Inc.	Treatment of depressive disorders
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049526B1 (ko) *	2018-06-05	2019-11-27	충남대학교산학협력단	Gaba를 유효성분으로 하는 항결핵 약학 조성물
KR102049522B1 (ko) *	2018-06-05	2019-11-27	충남대학교산학협력단	Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
EP3833351A4 (en)	2018-09-20	2021-10-13	Ovid Therapeutics Inc.	USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko)	2018-11-21	2021-09-08	썰테고 테라퓨틱스 아이엔씨.	자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es)	2018-12-17	2021-09-23	Ovid Therapeutics Inc	Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
KR20220008824A (ko)	2019-04-17	2022-01-21	컴퍼스 패쓰파인더 리미티드	실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
US11364228B2 (en)	2019-12-18	2022-06-21	Ovid Therapeutics Inc.	Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en)	2020-05-20	2023-01-01	Certego Therapeutics Inc	Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114404437A (zh) *	2022-03-15	2022-04-29	山东中医药大学	没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362731A (en) *	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) *	1987-08-25	1992-06-09	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
CA2118938A1 (en) *	1991-09-13	1993-04-01	Kelvin W. Gee	Novel gabaa receptor with steroid binding sites
US5206415A (en) *	1991-12-20	1993-04-27	Washington University	Tricyclic steroid analogs
CZ300694A3 (en) *	1993-12-02	1996-05-15	Akzo Nobel Nv	Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
BR9509764A (pt) *	1994-11-23	1998-07-07	Cocensys Inc	Série androstano e pregnano para modulação alostérica de receptor de gaba
US5776959A (en) *	1995-06-05	1998-07-07	Washington University	Anticonvulsant and anxiolytic lactam and thiolactam derivatives
PT837874E (pt) *	1995-06-06	2005-03-31	Euro Celtique Sa	Esteroides neuroactivos da serie androstano e pregnano
IT1290003B1 (it) *	1997-03-03	1998-10-19	Angelini Ricerche Spa	Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) *	1998-01-21	1998-03-18	Merck Sharp & Dohme	Therapeutic agents
DK1098871T3 (da) *	1998-07-22	2003-10-27	Akzo Nobel Nv	Phenylesterderivater af alfa-aminosyrer
BR0016201A (pt) *	1999-12-08	2002-08-13	Warner Lambert Co	Método para a sìntese estereosseletiva de aminoácidos cìclicos

2001
- 2001-11-16 AR ARP010105378A patent/AR031473A1/es unknown
- 2001-11-20 BR BR0115668-3A patent/BR0115668A/pt not_active Application Discontinuation
- 2001-11-20 AU AU2351402A patent/AU2351402A/xx active Pending
- 2001-11-20 EP EP01996378A patent/EP1337247B1/en not_active Expired - Lifetime
- 2001-11-20 NZ NZ525520A patent/NZ525520A/en unknown
- 2001-11-20 EA EA200300594A patent/EA007287B1/ru not_active IP Right Cessation
- 2001-11-20 YU YU39003A patent/YU39003A/sh unknown
- 2001-11-20 HR HR20030404A patent/HRP20030404A2/hr not_active Application Discontinuation
- 2001-11-20 CN CNB018190936A patent/CN1318027C/zh not_active Expired - Fee Related
- 2001-11-20 JP JP2002542383A patent/JP4152186B2/ja not_active Expired - Fee Related
- 2001-11-20 AU AU2002223514A patent/AU2002223514B2/en not_active Ceased
- 2001-11-20 UA UA2003054188A patent/UA77403C2/uk unknown
- 2001-11-20 DK DK01996378T patent/DK1337247T3/da active
- 2001-11-20 IL IL15558701A patent/IL155587A0/xx unknown
- 2001-11-20 PL PL36105101A patent/PL361051A1/xx unknown
- 2001-11-20 SK SK768-2003A patent/SK7682003A3/sk not_active Application Discontinuation
- 2001-11-20 ES ES01996378T patent/ES2266308T3/es not_active Expired - Lifetime
- 2001-11-20 DE DE60122368T patent/DE60122368T2/de not_active Expired - Lifetime
- 2001-11-20 MX MXPA03004349A patent/MXPA03004349A/es active IP Right Grant
- 2001-11-20 AT AT01996378T patent/ATE336242T1/de active
- 2001-11-20 KR KR1020037006754A patent/KR100865651B1/ko not_active Expired - Fee Related
- 2001-11-20 CA CA002429220A patent/CA2429220C/en not_active Expired - Fee Related
- 2001-11-20 ME MEP-64/08A patent/MEP6408A/xx unknown
- 2001-11-20 PT PT01996378T patent/PT1337247E/pt unknown
- 2001-11-20 HU HU0400505A patent/HUP0400505A3/hu unknown
- 2001-11-20 CZ CZ20031383A patent/CZ20031383A3/cs unknown
- 2001-11-20 WO PCT/DK2001/000773 patent/WO2002040009A1/en not_active Ceased
- 2001-11-20 SI SI200130619T patent/SI1337247T1/sl unknown
2003
- 2003-04-29 ZA ZA2003/03289A patent/ZA200303289B/en unknown
- 2003-04-30 IS IS6803A patent/IS2427B/is unknown
- 2003-05-01 US US10/430,704 patent/US20040024038A1/en not_active Abandoned
- 2003-05-20 NO NO20032271A patent/NO20032271D0/no not_active Application Discontinuation
- 2003-06-13 BG BG107909A patent/BG107909A/bg unknown
2006
- 2006-10-20 CY CY20061101505T patent/CY1106209T1/el unknown
2008
- 2008-06-27 US US12/163,883 patent/US20090143435A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR031473A1 (es)	2003-09-24
US20090143435A1 (en)	2009-06-04
SK7682003A3 (en)	2003-10-07
US20040024038A1 (en)	2004-02-05
CA2429220C (en)	2009-09-15
NZ525520A (en)	2005-04-29
DK1337247T3 (da)	2006-12-04
HRP20030404A2 (en)	2005-04-30
IL155587A0 (en)	2003-11-23
IS2427B (is)	2008-10-15
CN1318027C (zh)	2007-05-30
DE60122368D1 (de)	2006-09-28
CZ20031383A3 (cs)	2003-08-13
KR20030065517A (ko)	2003-08-06
HK1075010A1 (en)	2005-12-02
JP2004513921A (ja)	2004-05-13
KR100865651B1 (ko)	2008-10-29
MXPA03004349A (es)	2003-08-19
PL361051A1 (en)	2004-09-20
MEP6408A (xx)	2010-02-10
SI1337247T1 (sl)	2006-12-31
PT1337247E (pt)	2006-11-30
AU2351402A (en)	2002-05-27
BG107909A (bg)	2004-08-31
NO20032271L (no)	2003-05-20
EA200300594A1 (ru)	2003-10-30
UA77403C2 (en)	2006-12-15
BR0115668A (pt)	2003-09-02
EA007287B1 (ru)	2006-08-25
EP1337247B1 (en)	2006-08-16
ZA200303289B (en)	2005-07-27
ES2266308T3 (es)	2007-03-01
HUP0400505A2 (hu)	2004-07-28
EP1337247A1 (en)	2003-08-27
CA2429220A1 (en)	2002-05-23
CY1106209T1 (el)	2011-06-08
HUP0400505A3 (en)	2008-08-28
NO20032271D0 (no)	2003-05-20
YU39003A (sh)	2006-05-25
ATE336242T1 (de)	2006-09-15
AU2002223514B2 (en)	2006-11-30
WO2002040009A1 (en)	2002-05-23
JP4152186B2 (ja)	2008-09-17
DE60122368T2 (de)	2007-08-09
CN1592616A (zh)	2005-03-09

Publication	Publication Date	Title
NO20031442L (no)	2003-05-26	Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
NO20032271D0 (no)	2003-05-20	GABA-enhancere i behandlingen av sykdommer relatert til redusert nevrosteroidaktivitet
NO20044054L (no)	2004-11-24	Administrering av midler for behandling av betennelse
IS8233A (is)	2006-01-16	Própíónsýruafleiður sem eru gagnlegar í meðhöndlun á fitusjúkdómum
IS7814A (is)	2005-04-20	Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
ATE374196T1 (de)	2007-10-15	Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
IL155092A0 (en)	2003-10-31	Compounds useful in the treatment of inflammatory diseases
ATE441417T1 (de)	2009-09-15	Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
NO20026008L (no)	2002-12-13	Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
DE60031710D1 (de)	2006-12-14	Fettsäurederivat zur behandlung von externen sekretionsstörungen
EP1450837A4 (en)	2006-01-04	INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
GB0113502D0 (en)	2001-07-25	A method of incentivising members of a disease management programme to comply with the programme
IS7456A (is)	2004-09-17	Fosfat forlyf flúoróoxindóla
ID26441A (id)	2000-12-28	Proses untuk memproduksi ftalat anhidrida
IS7528A (is)	2004-11-15	Nýir etónógestrel esterar
IS7444A (is)	2004-09-13	Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
AU2002210385A1 (en)	2002-04-29	Furazanyl-triazole derivates for the treatment of diseases
IS6137A (is)	2001-10-30	Meðhöndlun á hugsýkistruflunum
FI20020593A0 (fi)	2002-03-27	Menetelmä konjugoidun linolihapon valmistamiseksi
DK1309322T3 (da)	2006-10-23	Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
NO20014081D0 (no)	2001-08-22	Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier
ID24405A (id)	2000-07-20	Pembnalut kesehatan yang dilengkapi dengan sayap
ITMI20001216A0 (it)	2000-05-31	Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica
IS7868A (is)	2005-05-26	Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
IS7537A (is)	2004-11-18	Notkun á nýjum etónógestrel esterum.